Our Footprint
A portfolio of products & service solutions to accelerate scientific discovery
5
500+
300,000+
7
Our Mission
Premium Portfolio
Custom Solutions
High Impact Expertise
Our Story
Fortis was founded in 2020 to support cutting-edge innovation in the life sciences and diagnostics industries. Today, we work with many of the world's leading companies across biopharma, diagnostics, academic research, government and applied industries. Our brands have a proud legacy of delivering high-quality products, paired with expert technical support, empowering customers to confidently bring their technologies to market.
Putting Down Roots in Texas with the Acquisition of Bethyl Labs
Big Innovation Comes in Small Particles
Fortis expanded its chemistry, diagnostic detection, and drug delivery capabilities with the acquisition of nanoComposix. NanoComposix is an industry leader in development and production of highly characterized nanomaterials which are critical components used in specialty therapeutics, diagnostics, and applied technologies.
Expanding from Proteomics to Genomics
The acquisition of Empirical Bioscience, Inc. marked Fortis' entry into genomic technologies and expanded our recombinant protein manufacturing capabilities. Empirical specializes in developing and manufacturing enzymes, buffers, master mixes, and molecular biology reagents. We recently expanded the enzyme and reagent catalog to further support R&D efforts for our diagnostics & genomics customers.
From the Bench to the Clinic
The addition of Arista Biologicals, Inc. expanded our antibody portfolio into the point-of-care diagnostic testing industry. Arista's portfolio of antibodies & other reagents is complemented by value-add services to support our customers including lateral flow assay design, custom conjugations, and assay development services.
Increasing the Speed of Antibody Discovery
Abcore LLC's robust technology platform added single-domain antibody discovery to Fortis' portfolio of antibody services. We have since developed the AbNanoTM VHH Naive Library, designed to improve research and clinical outcomes for our customers by delivering maximal discovery quality of antibody targets with low background.
Powering Global Diagnostic Testing Through Lyophilization
Fortis built upon our diagnostic reagent portfolio with the acquisition of International Point of Care, Inc. (IPOC). IPOC partners with global diagnostic customers to develop and manufacture lyophilized reagents for point-of-care molecular and immunodiagnostic testing. Lyophilization enhances product stability, reproducibility, quality, and shelf life, making it a vital technology for delivering reliable, accessible, and effective diagnostic solutions worldwide.
Advancements in Gene Delivery
Fortis expanded our therapeutics discovery platform with the acquisition of Vector Biolabs, a pioneer in viral vector design and production. Vector offers both catalog and comprehensive end-to-end AAV and AdV solutions to support our customers. Like other Fortis brands, Vector is committed to delivering reliable, consistent, and tailored solutions, increasing the speed to discovery for biopharma customers.
